[print friendly]

celecoxib (CELEBREX)

• celecoxib (CELEBREX); meloxicam (MOBIC); rofecoxib (VIOXX); valdecoxib (BEXTRA)
  We list these drugs as Do Not Use drugs because they are no more effective than related drugs, most have not been shown to have a lower rate of ulcers than related drugs and some have been shown to cause heart disease.

• Arthritis and Inflammation [hide all summaries]
  At least 31.6 million Americans suffer from some form of arthritis. The three most common types are rheumatoid arthritis, osteoarthritis, and gout. Each has a different cause, treatment, and probable outcome.
• Salicylates and Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) [hide all summaries]
  The salicylates are used to relieve pain and to reduce fever and inflammation. Aspirin, a nonsteroidal anti-inflammatory drug (NSAID), is the most well-known and frequently used salicylate. Other salicylates discussed on this web site are salsalate and choline and magnesium salicylates.

• Nonsteroidal Anti-Inflammatory Drugs Can Make Blood Pressure Hard to Control [hide all summaries]
  (February 2009)
  Twenty different NSAIDS (nonsteroidal antiinflammatory drugs) are listed in this article that can adversely affect your blood pressure control. The article discusses the way in which this happens and what you can do about it.
• Update on Drugs that Can Cause High Blood Potassium [hide all summaries]
  (December 2008)
  This article lists 68 drugs that can cause high blood potassium (hyperkalemia) that can result in nausea, fatigue, muscle weakness or tingling sensations, as well as heart abnormalities (showing up as an abnormal electrocardiogram). In some cases it can be fatal. If you are taking any of these drugs, be especially careful if you have diabetes or kidney disease. If so, you are at increased risk, and your doctor will have to weigh the risk of giving you these drugs. Also, the older you are, the more likely you are to develop hyperkalemia. Also, make sure you are receiving appropriate laboratory monitoring.
• Celecoxib (CELEBREX) May Double the Risk for Heart Attacks Compared to Older Arthritis Drugs [hide all summaries]
  (May 2006)
  New research published in the March 2006 edition of the Journal of the Royal Society of Medicine indicates that the popular arthritis and painkilling drug celecoxib (CELEBREX) may double the risk for heart attacks compared to older arthritis medications.
• FDA Public Health Advisory - Arthritis Drug Valdecoxib (BEXTRA) Removed From Market; Major New Warnings for Other NSAIDs [hide all summaries]
  (June 2005)
  If you are currently taking celecoxib (CELEBREX)you should contact your physician to consider alternative NSAID treatment.
• Cutting Your Drug Bill While Reducing Your Risk Of Avoidable Adverse Drug Reactions: Six Examples [hide all summaries]
  (February 2005)
  This article will look at the potential savings for the individual consumer if the alternative treatments recommended in Worst Pills, Best Pills were used for six DO NOT USE drugs. All six are listed in the Drug Topics Magazine Top 200 selling drugs in U.S. in 2003. The drugs are: celecoxib (CELEBREX) used for arthritis and pain; the Alzheimer’s disease drug donepezil (ARICEPT); drospirenone with ethinyl estradiol (YASMIN 28), an oral contraceptive; esomeprazole (NEXIUM) the “new purple pill” for heartburn; montelukast (SINGULAIR), a drug approved for both asthma and hay fever; and valdecoxib (BEXTRA), an arthritis drug very similar to celecoxib.The combined sales of these six DO NOT USE drugs was $8.1 billion with more that 75 million prescriptions dispensed in 2003.
• Alzheimer's Prevention Study Should Be Stopped [hide all summaries]
  (October 2002)
  On September 4, 2002, Public Citizen sent a letter to Health and Human Services (HHS) Secretary Tommy Thompson asking that an Alzheimer’s Disease (AD) prevention trial be immediately stopped and that the patients be provided with information on the risks to which they may already have been exposed.

• Letter to the FDA concerning Pfizer's 2 ½ minute television advertisement for Celebrex (HRG Publication #1803) [hide all summaries]
  We urge the Food and Drug Administration to order Pfizer to immediately stop its dangerous, misleading 2 ½ minute television advertisement for Celebrex that began airing on April 2nd.
• Bextra Ban a Good Step, But FDA Should Pull Celebrex Too (HRG Publication #1734) [hide all summaries]
  Statement of Sidney M. Wolfe, M.D., Director, Public Citizen's Health Research Group
• Painkillers and Terrorism. Letter to the Editor of the New York Times on Cox 2 Painkillers (HRG Publication #1727) [hide all summaries]
  Painkillers and Terrorism. Letter to the Editor of the New York Times on Cox 2 Painkillers (HRG Publication #1727)
• Testimony to FDA on Dangers of Cox-2 Drugs (HRG Publication #1725) [hide all summaries]
  Testimony of Sidney M. Wolfe, M.D. Director, Public Citizen’s Health Research Group (HRG) Before FDA Arthritis and Drug Safety Advisory Committees Concerning the Dangers of COX-2 Drugs
• Letter to FDA revealing heart dangers in an unpublished clinical trial of Celebrex (HRG Publication #1721) [hide all summaries]
  Trial revealing statistically significant heart dangers for Celebrex discovered on PhRMA website
• Petition to remove the Cox-2 Inhibitors Celecoxcib (CELEBREX) and Valdecoxcib (BEXTRA) From the Market (HRG Publication #1720) [hide all summaries]
  Petition to remove the Cox-2 Inhibitors Celecoxcib (CELEBREX) and Valdecoxcib (BEXTRA) From the Market (HRG Publication #1720)
• Vioxx, Other “Super Aspirins” Are Super Disasters – Other Cox-2 Alternatives Have Safety Problems Too (HRG Publication #1707) [hide all summaries]
  Vioxx, Other “Super Aspirins” Are Super Disasters – Other Cox-2 Alternatives Have Safety Problems Too (HRG Publication #1707)
• Letter to HHS Secretary Tommy Thompson that raises ethical concerns about the “Alzheimer’s Disease Anti-Inflammatory Prevention Trial” (ADAPT) (HRG Publication #1637) [hide all summaries]
  Because patients are taking drugs without true informed consent, Public Citizen urges the NIA to immediately stop this unethical trial and provide patients already enrolled in the trial with the information previously denied them on lack of plausible benefit as well as the possible health risks.
• Testimony before the FDA Arthritis Drugs Advisory Committee on the Nonsteroidal Anti-Inflammatory Drugs Celecoxib and Rofecoxib (HRG Publication #1555) [hide all summaries]
  A second box warning about cardiovascular toxicity needs to be added. It should warn of the lack of platelet aggregation inhibition of the drugs which protects those at risk from an increased occurrence of heart attacks. In addition, the evidence which is rapidly accumulating about the heart damage caused by these drugs must be mentioned in this cardiovascular box warning.
• Statement before the Food and Drug Administration's Arthritis Drugs Advisory Committee on the nonsteroidal anti-inflammatory drug celexocib. (HRG Publication #1465) [hide all summaries]
  There needs to be clear evidence from comparative long-term, higher dose randomized trials in which celecoxib or any other COX-2 type of anti-inflammatory drug is compared to the least dangerous of these older drugs, ibuprofen, that there is a statistically significantly lower amount of serious GI complications such as perforations, ulcers or bleeding with the COX-2 inhibitor drug.

• COX-2 Inhibitors Vioxx and Celebrex: Keep Staying Away--It Gets Worse [hide all summaries]
  (March 2001)
   In light of the above discussion, we continue to advise the patient-protective five-year-rule for these drugs, as we do for all other new drugs that are not breakthroughs. Do Not Use.

SHOW secondary search results for celecoxib (CELEBREX)